tiny-pdf-icon Reviva Pharmaceuticals Chosen as a 2018 Red Herring Top 100 North America Winner.(June 26, 2018)

tiny-pdf-icon Reviva granted FDA Orphan Drug Designation for RP5063 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).(April 10, 2018)

tiny-pdf-icon Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of                         Pulmonary Arterial Hypertension (PAH) (October 17, 2017)

tiny-pdf-icon Reviva Pharmaceuticals Announces Addition of a New Member to its Board of Directors (July 21, 2017)

tiny-pdf-icon Reviva Pharmaceuticals Announces Closing of Bridge Financing and Addition of a New Member to Its Board of Directors (May 22,          2017)

tiny-pdf-icon Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH) (Nov 17, 2016)

tiny-pdf-iconReviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American                    Thoracic Society Conference 2016 (May 19, 2016)

tiny-pdf-iconReviva Pharmaceuticals Reports RP5063 Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats (May 18,                    2016)

tiny-pdf-iconReviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits (October 22, 2015)

tiny-pdf-iconReviva Pharmaceuticals Appoints Three New Board Members (March 10, 2015)

tiny-pdf-iconReviva Pharmaceuticals Wins 2014 TiE50 Award (May 17, 2014)

tiny-pdf-iconReviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for RP5063 (November 4, 2013)

tiny-pdf-iconFeature Article on Reviva in BioWorld Today (September 3, 2013)

tiny-pdf-iconNovel antipsychotic RP5063 shows early promise – Clinical Psychiatry News (July 11, 2013)

tiny-pdf-iconReviva Pharmaceuticals Reports Positive Top-Line Results from a Phase 2 Clinical Trial of RP5063 for the Treatment         of Schizophrenia and Schizoaffective Disorder (April 9, 2013)

tiny-pdf-iconReviva Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of RP5063 for the Treatment         of Schizophrenia and Schizoaffective Disorder (January 14, 2013)
tiny-pdf-iconReviva presented RP5063 Phase 1 clinical results at the NCDEU conference (May 29-June 1, 2012)
tiny-pdf-iconReviva Pharmaceuticals Announces Enrollment of Patients in Phase 2 Clinical Study of RP5063 for the Treatment of         Schizophrenia and Schizoaffective Disorder (March 12, 2012)
Reviva interview with MergerMarket – A Financial Times Publication (February 6, 2012)

tiny-pdf-iconReviva News Release (September 2011)

tiny-pdf-iconIMS R&D Focus Drug News (November 2010)